SCHEMBL6136150

SCHEMBL6136150

CN(C(=O)NCCc1cccc(Cc2c(-c3ccc(O)cc3)ccc3cc(O)ccc23)c1)c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 6/20 0.39
▸ ESR1 P03372 3/20 0.36
▸ ESR2 Q92731 3/20 0.36
▸ TRPV1 Q8NER1 3/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ DNMT3A Q9Y6K1 1/20 0.34
▸ HTT P42858 1/20 0.33
▸ MTNR1A P48039 1/20 0.33
▸ MTNR1B P49286 1/20 0.33
▸ PDK1 Q15118 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ HSP90AB1 P08238 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135927 0.96 ESR1 (0.38) ESR1ESR2TRPV1MAPTMTNR1A
SCHEMBL6136267 0.92 OPRM1 (0.40) ESR1ESR2TRPV1GAAMAPT
SCHEMBL6136157 0.90 ESR1 (0.40) ESR1ESR2MAPTMTNR1AMTNR1B
SCHEMBL6136079 0.86 ESR1 (0.42) CNR1ESR1ESR2PDK1HSP90AA1
SCHEMBL6136184 0.83 CNR1 (0.54) CNR1TRPV1NPC1CYP1A2CYP2D6
SCHEMBL6136057 0.81 NPY5R (0.40) CNR1ESR1ESR2TRPV1
SCHEMBL6136101 0.81 ESR1 (0.46) ESR1ESR2TRPV1PDK1
SCHEMBL6136126 0.78 TRPV1 (0.47) CNR1ESR1ESR2TRPV1NPC1
SCHEMBL6136484 0.78 ESR1 (0.44) ESR1ESR2TRPV1
SCHEMBL6135989 0.78 GAA (0.40) CNR1ESR1ESR2TRPV1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback